spacer
home > epc > spring 2013 > an inside look
PUBLICATIONS
European Pharmaceutical Contractor

An Inside Look

EPC: What was your entry point into the pharmaceutical industry?

CS:
My career started in data management in Dublin. Following the completion of my Biotechnology degree from Dublin City University, I felt a drive towards business and finding a commercial application to my education, but was unsure of which areas to explore. A fortuitous meeting between my mother (a school headmistress) and one of her studentsí parents (an HR manager) led to my application to Quintiles and entry into the industry. I am still thanking them both for that, as over time I realised what a great opportunity it presented.

Which part of your current role do you most enjoy?

I value the responsibility of being in a leadership position. There is a simplicity that goes with knowing that, ultimately, a decision rests with you, and understanding that responsibility is important. I value the trust given to me by ICONís board and executive team (DOCS is a division of ICON), and the empowerment that comes with that. Having that level of responsibility sometimes means you have to take the rough with the smooth, but personally I find that energising.

Which part is the most challenging?

We have significant growth plans in DOCS, which means we are investing heavily in the business. At the same time, we need to stay focused on managing the day-to-day business. Finding a balance is often challenging.

How would you describe your business philosophy?

I have always believed that if you do the right things in the right way, the rewards will follow. Clients and staff appreciate a straightforward approach and usually understand decisions made in the context of doing things in the correct manner. Sometimes other business pressures can distract from that philosophy. However I believe in focusing on what is right for the business and its people.

What has been your proudest moment?

There have been many highlights associated with working and travelling abroad. I have enjoyed and learnt a lot about myself, not to mention the industry, and met some interesting and inspiring people. Probably the most intense and rewarding experience was working with colleagues in Asia Pacific, whose determination and ambition is always energising. I am also very proud of the progress DOCS has made and the growth we have seen in recent years.

And your greatest disappointment?

I try not to let myself get disappointed. Things happen for a reason and generally work out the way they should do. I have been lucky enough to be part of successful teams and a successful business, so when things havenít worked out, those outcomes have been insignifi cant relative to the overall positives.

What does the pharma sector need to focus on in 2013?

People. There has been a lot of change as organisations adapt to a shifting focus. Cost competitiveness is paramount. Technology is beginning to change peopleís roles. The pharma sector has increasing focus on value for money and maximising return. The successful companies will be those who best manage their resource and find resourcing solutions that reward staff while maximising return on investment.

How do you think the pharmaceutical industry as a whole will change over the next 10 years?

Technology will continue to drive effi ciency and provide intelligent information to study teams. There is an enticing promise of personalised medicine moving forward over the next decade which may lead to a reduction in the size of studies, but also a compensating increase in the number of compounds being pursued. And, as the pharma sector looks for more value from its service providers, it will seek partners who can offer a multitude of service options and outsourcing strategies.

What is the most important lesson you have learnt?

Commit to the vision. If you have a vision of where you want to go and what you want to achieve, then stay focused on it. There will be challenges along the way, but if you commit fully, you will get there.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Colin Stanley is President of DOCS. He has over 14 years of experience working in the CRO industry. Colin joined ICON in 2001 and has spent the last ten years in a number of leadership positions in the US, Europe and Asia-Pacific.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Companyís novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement